Company Overview of Danube Pharmaceuticals, Inc.
Danube Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the research and development of drugs and technologies for the treatment of ophthalmic and other related diseases. Its DNB-001 is a small molecule for the treatment of glaucoma. The company also engages in the research of efficacy of novel oral therapy with a dual mechanism of action, in lowering the intraocular pressure ("IOP") in patients with ocular hypertension. The company was incorporated in 2005 and is based in New York, New York.
689 Fifth Avenue
New York, NY 10022
Founded in 2005
Key Executives for Danube Pharmaceuticals, Inc.
Similar Private Companies By Industry
|Gritstone Oncology Inc.||United States|
|Chemogen, Inc.||United States|
|CureDM, Inc.||United States|
|TEF Labs, Inc.||United States|
|BioMarker Pharmaceuticals, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Danube Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.